Connolly Sarah T. Abb Vie Inc. Transaction History

Connolly Sarah T.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	SELL	$133.59 - $154.65 $10,019 - $11,598	-75 Reduced 1.14%	6,515 $971,000
Q4 2022 Feb 08, 2023	SELL	$138.31 - $165.87 $6,915 - $8,293	-50 Reduced 0.75%	6,590 $1.07 Million
Q4 2021 Feb 09, 2022	BUY	$107.43 - $135.93 $13,428 - $16,991	125 Added 1.92%	6,640 $899,000
Q3 2021 Oct 26, 2021	BUY	$106.4 - $120.78 $5,320 - $6,039	50 Added 0.77%	6,515 $703,000
Q2 2021 Jul 14, 2021	SELL	$105.21 - $117.21 $5,260 - $5,860	-50 Reduced 0.77%	6,465 $728,000
Q1 2021 Apr 26, 2021	SELL	$102.3 - $112.62 $2,557 - $2,815	-25 Reduced 0.38%	6,515 $705,000
Q4 2020 Feb 10, 2021	BUY	$80.49 - $108.67 $526,404 - $710,701	6,540 New	6,540 $701,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Connolly Sarah T., based on Form 13F filings with the SEC.

Stay updated on Connolly Sarah T. with notifications on news.